| NavigationINDEX |
Molecular Biology
On this page, we have put some data together abstracted from previous and
current work in our lab. We are still working on most of these studies, and the
tables will be updated as more data become available.
Part of this work was published in:
We also have an analysis of the
molecular modelling
aspects of this work on-line.
Before venturing into site-directed mutagenesis experiments, we devised a
strategy to detect receptors that lacked binding of radioligands. This would
enable us to distinguish between (greatly) reduced affinity of the mutant
receptors for the radioligands, and reduced expression levels of the mutant
protein at the cell-surface.
Thus, an immunologically detectable HA-tag (hemagglutinin) was inserted into the
human A2A adenosine receptor sequence (
Table I
) immediately following the first Met residue. The resulting
Tag1
receptor showed virtually the same affinity for [3H]CGS 21680 as
the wild type receptor (
Table II),
but could not be detected by ELISA, Western blotting, or immunocytochemistry.
Table I:
N-terminal sequences of epitope-tagged human A2A receptors.
|
wild type human A2A sequence
|
MPIMGSS..........
|
|
Tag1 sequence
|
MYPYDVPDYAPIMGSS..........
|
|
Tag2 sequence
|
MPIMYPYDVPDYAGSS..........
|
|
Tag3 sequence
|
PIMYPYDVPDYAGSS..........
|
Interestingly, there are two methionine residues in the amino-terminal
segment of the human A2A adenosine receptor. The introduction of an
HA-tag following the first Met might affect the initiation of protein
translation, causing protein expression to start at the second Met. This would
result in the deletion of the first 3 amino acids (MPI) and the HA-tag not
being translated. However, the resulting mutant receptor may still be
functional. We therefore introduced an HA-tag after the second Met (
Tag2
). This mutant receptor showed the same affinity for [3H]CGS 21680
and the same expression level (Bmax) as the non-tagged receptor(
Table II
). Moreover, the Tag2 receptor could also be detected by ELISA (but not
Western blotting).
Table II:
[3H]CGS 21680 binding properties of wild type (WT) and
three epitope-tagged human A2A adenosine receptor constructs.
|
construct
|
Kd
nM
|
Bmax
pmol/mg
|
|
A2A WT
|
15.9 ± 0.3
|
26.9 ± 13.3
|
|
Tag1
|
24.1 ± 0.1
|
24.3 ± 12.4
|
|
Tag2
|
23.8 ± 2.0
|
28.0 ± 14.4
|
|
Tag3
|
21.7 ± 2.6
|
35.4 ± 20.0
|
To test if the first Met is important for the expression of the receptor, we
deleted the first Met to construct
Tag3.
Again, the Tag3 receptor displayed affinity and expression levels similar to
the wild type receptor (
Table II
). We therefore concluded that the second Met may represent the physiological
translation start site in the human A2A adenosine receptor. Based
on these results, the Tag3 epitope-tag was used in further site-directed
mutagenesis studies.
First off, we tried to localize residues involved in ligand binding present
in the fifth, sixth and seventh transmembrane domains (TM5, TM6 & TM7;
Table III
).
Table III:
Effects on [3H]CGS 21680 binding to wild type (WT-Tag3)
and mutant human A2A receptors.
|
Kd/i (nM)
|
CGS 21680
|
CADO
|
NECA
|
R-PIA
|
CGS 15943
|
XAC
|
|
WT (Tag3)
|
21.7 ± 2.6
|
152 ± 10
|
19.9 ± 8.3
|
318 ± 8.0
|
10.0 ± 2.0
|
63.2 ± 5.5
|
|
F180A
|
15.1 ± 1.3
|
ND
|
46.0 ± 11.1
|
ND
|
13.7 ± 3.2
|
90.3 ± 7.2
|
|
N181S
|
24.8 ± 5.6
|
1340 ± 200
|
16.4 ± 2.5
|
4500 ± 1200
|
23.7 ± 2.0
|
130 ± 10.0
|
|
F182Y
|
57 ± 15
|
1890 ± 170
|
170 ± 11
|
2800 ± 1100
|
19.2 ± 4.2
|
140 ± 20.1
|
|
F182W
|
66 ± 6
|
776 ± 120
|
144 ± 12
|
1600 ± 460
|
10.3 ± 3.3
|
66.8 ± 1.0
|
|
H250Y
|
14.9 ± 1.0
|
8250 ± 1400
|
43.8 ± 16
|
9580 ± 280
|
8.4 ± 1.0
|
52.7 ± 11
|
|
H250F
|
14.4 ± 4.0
|
2130 ± 100
|
41.9 ± 12
|
7950 ± 1750
|
25.7 ± 5.0
|
60.3 ± 3.0
|
|
C254A
|
23.7 ± 2.4
|
ND
|
18.2 ± 10.3
|
ND
|
19.4 ± 3.4
|
54.1 ± 8.2
|
|
S281T
|
17.1 ± 2.0
|
13.7 ± 1.3
|
6.6 ± 0.8
|
30.5 ± 8.6
|
15.6 ± 3.4
|
17.3 ± 1.6
|
In general, these mutations did not affect the affinity of antagonists
(such as CGS 15943 and XAC), but the effects on agonist
(CGS 21680, CADO, NECA, and R-PIA) binding were more intricate.
The F180A, and C254A mutant receptors showed ligand binding properties similar
to those of the wild type receptor. Therefore, the aromatic group in F180,
and the thiol group in C254 are not required for binding of agonists or
antagonists.
A detailed analysis of these results is provided in
our paper cited above.
A particular residue in TM7 (S277) had some very interesting features.
We decided to have a closer look, and measured both [3H]CGS 21680
binding when possible and [3H]XAC binding when
[3H]CGS 21680 binding was virtually absent (
Table IV
).
Table IV:
Radioligand binding to human A2A receptors.
|
Kd/i (nM)
|
CGS 21680
|
CADO
|
NECA
|
R-PIA
|
CGS 15943
|
XAC
|
|
[3H]CGS 21680
|
|
WT (Tag3)
|
21.7 ± 2.6
|
152 ± 10
|
19.9 ± 8.3
|
318 ± 8.0
|
10.0 ± 2.0
|
63.2 ± 5.5
|
|
S277A
|
< 2 % SB
|
|
|
|
|
|
|
S277N
|
25.0 ± 5.0
|
221 ± 21
|
43.0 ± 17.1
|
631 ± 329
|
12.8 ± 2.8
|
60.0 ± 17.4
|
|
S277T
|
23.6 ± 6.3
|
201 ± 5.0
|
39.8 ± 6.9
|
534 ± 152
|
12.2 ± 1.0
|
65.9 ± 2.2
|
|
S277C
|
37.2 ± 1.2
|
384 ± 22
|
129 ± 12
|
1588 ± 570
|
1.53 ± 1.1
|
10.3 ± 4.6
|
|
[3H]XAC
|
|
WT (Tag3)
|
40.7 ± 9.5
|
208 ± 66.4
|
72.5 ± 10.0
|
792 ± 49.9
|
20.7 ± 0.8
|
9.4 ± 2.3
|
|
S277A
|
~ 43600
|
~ 81300
|
~ 29100
|
~ 33800
|
17.5 ± 4.1
|
6.7 ± 1.2
|
Some mutants simply prevented ligand binding at all, regardless of whether the
receptor was expressed at the cell surface (measured by immunological detection
of the Tag3 sequence), or whether the (mutant) receptor was present and
could still activate adenylyl cyclase (
Table V
).
Table V:
Detrimental Mutations to human A2A receptors.
|
mutant(s)
|
[3H]CGS 21680
|
[3H]XAC
|
expression
level (%)
|
adenylyl cyclase
(EC50; nM)
|
|
WT (Tag3)
|
+
|
+
|
100
|
3.0 ± 1.0
|
|
F182A
|
-
|
-
|
71 ± 13
|
|
|
H250A
|
-
|
-
|
58 ± 1
|
|
|
N253A,Q,S
|
-
|
-,-,-
|
40 ± 6 (A)
|
|
|
F257A
|
-
|
-
|
68 ± 16
|
|
|
I274A
|
-
|
-
|
72 ± 15
|
100 ± 20
|
|
S277A
|
-
|
+
|
25 ± 6
|
210 ± 35
|
|
H278A,F,Q,Y
|
-
|
-,-,-,-
|
72 ± 24 (A)
|
920 ± 70 (A)
|
|
S281A
|
-
|
-
|
36 ± 7
|
|
If you would like to know more about
you have found the right spot:
|